AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23909286 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord plasma insulin
Number of subjects: 208
Study 23909286 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratification by gender
Number of subjects: 208
Study 21752462 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding peer counselling (one antenatal visit and four post-delivery visits)
Number of subjects: 2579
Study 21752462 — intervention group
Group type: COMPARATOR
Intervention: Control (no peer counselling)
Number of subjects: 2579
Study 21752462 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding peer counselling
Number of subjects: 2579
Study 19188575 — intervention group
Group type: EXPERIMENTAL
Intervention: XP13512 1,200 mg once daily
Number of subjects: 222
Study 19188575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 17101479 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopiroxolamine/Zinc Pyrithione shampoo (1.5% CPO/1% ZP)
Number of subjects: 189
Study 17101479 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole gel (2%)
Number of subjects: 189
Study 17101479 — intervention group
Group type: COMPARATOR
Intervention: Vehicle shampoo
Number of subjects: 189
Study 15553106 — intervention group
Group type: EXPERIMENTAL
Intervention: emedastine 4 mg o.d.
Number of subjects: 120
Study 15553106 — intervention group
Group type: COMPARATOR
Intervention: cetirizine 10 mg o.d.
Number of subjects: 120
Study 11708590 — intervention group
Group type: EXPERIMENTAL
Intervention: Imitation sessions
Number of subjects: 20
Study 11708590 — intervention group
Group type: COMPARATOR
Intervention: Control group (playing with the child)
Number of subjects: 20
Study 9179098 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 23
Study 9179098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 7956403 — intervention group
Group type: EXPERIMENTAL
Intervention: 27-gauge needle
Number of subjects: 625
Study 7956403 — intervention group
Group type: COMPARATOR
Intervention: 30-gauge needle
Number of subjects: 625
Study 31443735 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (rehabilitation treatment)
Number of subjects: 20
Study 31443735 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 27834492 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot Crystals (BC)
Number of subjects: 8
Study 27834492 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (Bi)
Number of subjects: 8
Study 27834492 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Beetroot Crystals and Sodium Bicarbonate (BC+Bi)
Number of subjects: 8
Study 27834492 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8
Study 25638483 — intervention group
Group type: EXPERIMENTAL
Intervention: Bear Essentials parent training plus distraction
Number of subjects: 90
Study 25638483 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction only
Number of subjects: 90
Study 25638483 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 23972452 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 171
Study 23972452 — intervention group
Group type: COMPARATOR
Intervention: Ajust
Number of subjects: 171
Study 21324184 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly docetaxel-based chemotherapy
Number of subjects: 139
Study 21324184 — intervention group
Group type: COMPARATOR
Intervention: 3-weekly docetaxel-based chemotherapy
Number of subjects: 139
Study 18304128 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 7 micro/kg
Number of subjects: 23
Study 17699253 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (prednisolone, azathioprine, warfarin, and dipyridamole)
Number of subjects: 80
Study 17699253 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone alone
Number of subjects: 80
Study 17699253 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment and Prednisolone alone
Number of subjects: 80
Study 12714472 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (spinal mobilisation)
Number of subjects: 183
Study 12714472 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy (mainly exercise)
Number of subjects: 183
Study 12714472 — intervention group
Group type: COMPARATOR
Intervention: General practitioner care (counselling, education, and drugs)
Number of subjects: 183
Study 12714472 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 183
Study 12714472 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 183
Study 12714472 — intervention group
Group type: COMPARATOR
Intervention: General practitioner care
Number of subjects: 183
Study 10917579 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) infusion
Number of subjects: 44
Study 10917579 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) infusion
Number of subjects: 44
Study 10917579 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelium-dependent flow reserve
Number of subjects: 44
Study 10917579 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting forearm blood flow (FBF)
Number of subjects: 44
Study 8923338 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloninger Temperament and Character Inventory (TCI)
Number of subjects: 103
Study 8923338 — intervention group
Group type: EXPERIMENTAL
Intervention: Millon Clinical Multiaxial Inventory (MCMI‐II)
Number of subjects: 103
Study 8923338 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloninger's character dimensions (self-transcendence)
Number of subjects: 103
Study 1572459 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg and dipyridamole 150 mg twice daily
Number of subjects: 145
Study 1572459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 1572459 — intervention group
Group type: EXPERIMENTAL
Intervention: No detectable serum concentration (less than 50 ng ml‐1)
Number of subjects: 145
Study 1572459 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected for risk factors
Number of subjects: 145
Study 3863219 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin sodium
Number of subjects: 0
Study 3863219 — intervention group
Group type: COMPARATOR
Intervention: Imipenem alone
Number of subjects: 0
Study 3863219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilastatin
Number of subjects: 0
Study 30636626 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 248
Study 30636626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 29500675 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational multivitamin
Number of subjects: 56
Study 29500675 — intervention group
Group type: COMPARATOR
Intervention: Standard multivitamin
Number of subjects: 56
Study 23683727 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral DXA for women
Number of subjects: 2964
Study 23683727 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral DXA for men
Number of subjects: 2964
Study 23683727 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral femoral DXA for women
Number of subjects: 2964
Study 23683727 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral femoral DXA
Number of subjects: 2964
Study 23107780 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin 2 grams/day
Number of subjects: 36
Study 23107780 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin 4 grams/day
Number of subjects: 36
Study 23107780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 20305368 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 400 IU/day + calcium 500 mg/day (D/Cal group)
Number of subjects: 70
Study 20305368 — intervention group
Group type: COMPARATOR
Intervention: Placebo + calcium 500 mg/day (Plac/Cal group)
Number of subjects: 70
Study 16919319 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg D‐amphetamine
Number of subjects: 44
Study 16919319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 16919319 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress reactivity
Number of subjects: 44
Study 16325037 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg/day (F group)
Number of subjects: 40
Study 16325037 — intervention group
Group type: COMPARATOR
Intervention: Control group (diet) (C group)
Number of subjects: 40
Study 12065465 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 44
Study 12065465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 9484961 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether (intramuscular injection)
Number of subjects: 164
Study 9484961 — intervention group
Group type: COMPARATOR
Intervention: Quinine (intravenous infusion)
Number of subjects: 164
Study 7658952 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic training
Number of subjects: 32
Study 7658952 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic preload knee extension resistance training
Number of subjects: 32
Study 7658952 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic training
Number of subjects: 32
Study 7658952 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 2692820 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg twice daily
Number of subjects: 114
Study 2692820 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 114
Study 62992 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol
Number of subjects: 0
Study 62992 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chloramphenicol
Number of subjects: 0
Study 62992 — intervention group
Group type: COMPARATOR
Intervention: Parenteral chloramphenicol
Number of subjects: 0
Study 62992 — intervention group
Group type: COMPARATOR
Intervention: Parenteral ampicillin
Number of subjects: 0
Study 62992 — intervention group
Group type: COMPARATOR
Intervention: Oral co‐trimoxazole
Number of subjects: 0
Study 31520255 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive care (PC)
Number of subjects: 20
Study 31520255 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 20
Study 31081371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 1544
Study 31081371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 1544
Study 31081371 — intervention group
Group type: COMPARATOR
Intervention: Ertugliflozin
Number of subjects: 1544
Study 27842473 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Hope Box (VHB)
Number of subjects: 118
Study 27842473 — intervention group
Group type: COMPARATOR
Intervention: Control group (printed materials about coping with suicidality)
Number of subjects: 118
Study 25885325 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E vaccine (0-1-2-month schedule)
Number of subjects: 0
Study 24053420 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication with significant adults about sexuality issues
Number of subjects: 6251
Study 24053420 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison schools)
Number of subjects: 6251
Study 21836134 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP withdrawal (subtherapeutic CPAP)
Number of subjects: 41
Study 21836134 — intervention group
Group type: COMPARATOR
Intervention: Continued CPAP (control)
Number of subjects: 41
Study 19162029 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated intervention (performed by a registered nurse before discharge and repeated at 6-month intervals)
Number of subjects: 120
Study 19162029 — intervention group
Group type: COMPARATOR
Intervention: Initial intervention only (control group)
Number of subjects: 120
Study 19162029 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated intervention (after 6 months)
Number of subjects: 120
Study 17284262 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-fluoroscopy guidance
Number of subjects: 50
Study 17284262 — intervention group
Group type: COMPARATOR
Intervention: Control (no CT-fluoroscopy guidance)
Number of subjects: 50
Study 12871363 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin for 5 weeks after HRS
Number of subjects: 218
Study 12871363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 12871363 — intervention group
Group type: COMPARATOR
Intervention: Placebo with venographically proven DVT
Number of subjects: 218
Study 12871363 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin and DVT risk
Number of subjects: 218
Study 10865409 — intervention group
Group type: EXPERIMENTAL
Intervention: beta thal/HbE postsplenec
Number of subjects: 28
Study 9174388 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 treatment (60 micrograms PGE1 in 250 ml of physiological saline, twice daily for 3 weeks)
Number of subjects: 83
Study 9174388 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 treatment
Number of subjects: 83
Study 1359619 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT (300 mg/day) + ACV (600 mg/day)
Number of subjects: 26
Study 1359619 — intervention group
Group type: COMPARATOR
Intervention: AZT (300 mg/day)
Number of subjects: 26
Study 1359619 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT + ACV (in patients with >200 CD4 cells/microL at diagnosis)
Number of subjects: 26
Study 1359619 — intervention group
Group type: COMPARATOR
Intervention: AZT (in patients with <200 CD4 cells/microL at diagnosis)
Number of subjects: 26
Study 1359619 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT + ACV
Number of subjects: 26
Study 1359619 — intervention group
Group type: COMPARATOR
Intervention: AZT
Number of subjects: 26
Study 1359619 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 26
Study 3099268 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (20 mg/kg/day for 10 days)
Number of subjects: 104
Study 3099268 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V potassium (20 mg/kg/day for 10 days)
Number of subjects: 104
Study 3099268 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cephalosporins (combined data from five studies)
Number of subjects: 104
Study 3099268 — intervention group
Group type: COMPARATOR
Intervention: Penicillin (combined data from five studies)
Number of subjects: 104
Study 30624003 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal Root Ganglion (DRG) stimulation
Number of subjects: 75
Study 30624003 — intervention group
Group type: COMPARATOR
Intervention: Spinal Cord Stimulation (SCS)
Number of subjects: 75
Study 29129253 — intervention group
Group type: EXPERIMENTAL
Intervention: Orsiro bioresorbable polymer sirolimus‐eluting stent (BP SES)
Number of subjects: 1334
Study 29129253 — intervention group
Group type: COMPARATOR
Intervention: Xience durable polymer everolimus‐eluting stent (DP EES)
Number of subjects: 1334
Study 26831677 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 62
Study 26831677 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid cardioplegia
Number of subjects: 62
Study 25095846 — intervention group
Group type: EXPERIMENTAL
Intervention: Kefir drink (100 ml per day for 2 weeks)
Number of subjects: 22
Study 25095846 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride rinse (0.05% for 2 weeks)
Number of subjects: 22
Study 25095846 — intervention group
Group type: COMPARATOR
Intervention: Kefir drink (after washout period)
Number of subjects: 22
Study 25095846 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride rinse (after washout period)
Number of subjects: 22
Study 22721966 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose
Number of subjects: 24
Study 22721966 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal nutrition perfusion
Number of subjects: 24
Study 22721966 — intervention group
Group type: EXPERIMENTAL
Intervention: Exendin(9-39) infusion
Number of subjects: 24
Study 22721966 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-related stimulation of ISR
Number of subjects: 24
Study 22721966 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 and GIP secretions
Number of subjects: 24
Study 22721966 — intervention group
Group type: EXPERIMENTAL
Intervention: Incretin effect
Number of subjects: 24
Study 19670096 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy combined with regional hyperthermia (RHT)
Number of subjects: 46
Study 17924282 — intervention group
Group type: EXPERIMENTAL
Intervention: TVE‐DSE in DM + MA
Number of subjects: 71
Study 17924282 — intervention group
Group type: EXPERIMENTAL
Intervention: TVE‐DSE in DM - MA
Number of subjects: 71
Study 17924282 — intervention group
Group type: COMPARATOR
Intervention: TVE‐DSE in Controls
Number of subjects: 71
Study 15141795 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 1 and 2 MAC in nitrous oxide/oxygen (55%/45%)
Number of subjects: 0
Study 15141795 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1 and 2 MAC in nitrous oxide/oxygen (55%/45%)
Number of subjects: 0
Study 15141795 — intervention group
Group type: COMPARATOR
Intervention: Both desflurane and sevoflurane
Number of subjects: 0
Study 11588634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 9861862 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B surface antigen (HbsAg) and antibodies to hepatitis B virus (anti‐HBV)
Number of subjects: 63
Study 9861862 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti‐HCV
Number of subjects: 63
Study 9861862 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti‐HTLV‐1
Number of subjects: 63
Study 9861862 — intervention group
Group type: COMPARATOR
Intervention: Anti‐HIV and anti‐HDV
Number of subjects: 63
Study 10158378 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnum 0.021 inch wire
Number of subjects: 723
Study 2778791 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril (20-40 mg once daily)
Number of subjects: 12
Study 2778791 — intervention group
Group type: COMPARATOR
Intervention: captopril (25-50 mg twice daily)
Number of subjects: 12
Study 2778791 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 12
Study 2778791 — intervention group
Group type: COMPARATOR
Intervention: captopril
Number of subjects: 12
Study 321288 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofenate
Number of subjects: 47
Study 321288 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibate
Number of subjects: 47
Study 321288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 321288 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofenate with phenformin plus chlorpropamide or tolbutamide
Number of subjects: 47
Study 321288 — intervention group
Group type: COMPARATOR
Intervention: Insulin treatment
Number of subjects: 47
Study 321288 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 47
Study 31674091 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned Vaginal Delivery (VD)
Number of subjects: 1391
Study 31674091 — intervention group
Group type: COMPARATOR
Intervention: Planned Cesarean Delivery (CD)
Number of subjects: 1391
Study 31820116 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated reminder calls in addition to usual care
Number of subjects: 301
Study 31820116 — intervention group
Group type: COMPARATOR
Intervention: Usual care telephone reminders
Number of subjects: 301
Study 28832557 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional care plus self‐efficacy interventions (health education, behavior therapy, psychological intervention)
Number of subjects: 120
Study 28832557 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (control group)
Number of subjects: 120
Study 28832557 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional care plus self‐efficacy interventions
Number of subjects: 120
Study 23186131 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 90
Study 23186131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 21108868 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat simulation group (assessed immediately after battlefield simulation)
Number of subjects: 0
Study 21108868 — intervention group
Group type: COMPARATOR
Intervention: Control group (assessed shortly before battlefield simulation)
Number of subjects: 0
Study 19749494 — intervention group
Group type: EXPERIMENTAL
Intervention: efonidipine hydrochloride ethanolate 40 mg/day
Number of subjects: 40
Study 19749494 — intervention group
Group type: COMPARATOR
Intervention: amlodipine besilate 5 mg/day
Number of subjects: 40
Study 17093150 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg Cuban sugar cane policosanol (SCP) per day
Number of subjects: 21
Study 17093150 — intervention group
Group type: COMPARATOR
Intervention: Placebo (incorporated in margarine)
Number of subjects: 21
Study 15055092 — intervention group
Group type: EXPERIMENTAL
Intervention: High-strength magnetic knee sleeve treatment
Number of subjects: 29
Study 15055092 — intervention group
Group type: COMPARATOR
Intervention: Placebo-magnetic knee sleeve treatment
Number of subjects: 29
Study 11717621 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure patients (mild-to-moderate symptoms, NYHA classes I and II)
Number of subjects: 24
Study 11717621 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure patients (severe symptoms, NYHA classes III and IV)
Number of subjects: 24
Study 11717621 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure patients (all classes)
Number of subjects: 24
Study 11717621 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure patients (adjusted for confounders)
Number of subjects: 24
Study 9156046 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (2 cigarettes) in diabetic smokers
Number of subjects: 20
Study 9156046 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (2 cigarettes) in normal smokers
Number of subjects: 20
Study 9156046 — intervention group
Group type: COMPARATOR
Intervention: Insulin tolerance test (0.15 U/kg body weight) in diabetic smokers
Number of subjects: 20
Study 9156046 — intervention group
Group type: COMPARATOR
Intervention: Insulin tolerance test (0.15 U/kg body weight) in normal non-smokers
Number of subjects: 20